Sequence 26 from Patent US 20060122119
General Information
DRACP ID DRACP01282
Peptide Name Sequence 26 from Patent US 20060122119
Sequence TPRLPSSADVE
Sequence Length 11
UniProt ID P11344 Q8MIU0 P54834 Q9BDE0 P55033 P14679
PubChem CID Not available
Origin Homo sapiens
Type Native peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Not available
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification None
Chiral L
Physicochemical Information
Formula C49H82N14O19
Absent amino acids CFGHIKMNQWY
Common amino acids PS
Mass 134981
Pl 4.18
Basic residues 1
Acidic residues 2
Hydrophobic residues 3
Net charge -1
Boman Index -2905
Hydrophobicity -65.45
Aliphatic Index 70.91
Half Life
Mammalian: 7.2 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2006/0122119 A1
Patent Title Peptides for use in antitumor immunotherapy.
Other Iinformation Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002
Other Published ID CA2477762A1 EP1481009A2 WO2003074565A2 WO2003074565A3